Conclusions
We have shown that CrCl can be accurately predicted one day in advance during ICU stay. We have also demonstrated the robustness of the developed models on previously unseen patients in external validation. The developed models’ usefulness has been shown in comparison with a reference reflecting current clinical practice, mainly on the patient-days with high kidney function instability. Despite the promising performance, these findings should be prospectively validated in independent patient populations, before these prediction models can be further used for risk stratification or incorporated into a pharmacokinetic model to support a more optimized dose regimen.